Loading organizations...
GL Capital is a Beijing, China-based private equity firm that provides capital and strategic support to middle-market healthcare companies operating throughout the Chinese market. The firm raises private equity vehicles backed by institutional investors like insurers, generating its revenue through management fees and carried interest based on fund performance. As of August 2025, the organization maintains total assets under management exceeding $3.9 billion across its various investment vehicles, including the GL China Opportunities Fund V. In September 2025, the firm closed a $240 million single-asset continuation fund that received direct backing from the Abu Dhabi Investment Authority. The investment team features several notable industry executives, including former Novartis China president Jeffrey Li, alongside directors and partners such as Alex Xia, Amber Miao, and Dalin Cao. GL Capital was founded in 2010 by Jeffrey Li.
GL Capital has 4 tracked investments across 2 companies. The latest tracked deal is $190.0M Series A in New Amsterdam Pharma in January 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2021 | New Amsterdam Pharma | $190.0M Series A | Ascendant BioCapital, Forbion, Jason Dinges | Founders Fund, Presight Capital, Peter Thiel, BVF Partners, Janus Henderson Investors, JVC Investment Partners, Kaiser Permanente, LSP, Medpace, Population Health Partners |
| Apr 18, 2014 | Arrail Dental Clinic | $70.0M Other Equity | NEW Horizon Capital | Commonfund, Elite Capital, KPCB China, Prometheus Capital, Qiming Venture Partners |
| Apr 1, 2014 | Arrail Dental Clinic | $70.0M Series C | NEW Horizon Capital | Qiming Venture Partners, Commonfund, Elite Capital, KPCB China, Prometheus Capital |
| Jul 1, 2011 | Arrail Dental Clinic | $20.0M Series B | GL Capital | Qiming Venture Partners, KPCB China |
